Biological Material Analysis TRIZ Cases

Optimized CDR sequences raise PD-L1 binding affinity, block PD-1 signaling, and improve T cell killing on low-expression tumors.

Reduced CD127 expression enables more specific isolation of FoxP3-enriched suppressive Tregs for expansion and immune disorder therapy.

Using PBMCs in 384-well plates with up to 175 μL medium cuts reagent use while enabling high-throughput animal-free pyrogen detection.

Real-time fluorescence in a microfluidic assay tracks platelet and fibrin buildup to reveal clotting and bleeding risk for urgent care decisions.

Integrated hematocrit imaging in a lateral flow blood assay improves plasma analyte accuracy without external equipment or reagents.

Specific MUC17-binding antibodies improve tumor expression detection and quantification to guide diagnosis, stratification, and treatment response monitoring.

Plant ER microsomes enable fast, reproducible ligand screening for correctly folded transmembrane proteins without complex cell-based production.

A microneedle array localizes recognition molecules on each needle to detect multiple biomarkers rapidly and accurately without lab instruments.

Colorimetric reactant and control regions turn bodily discharge into clear visual signals for non-invasive detection of reproductive and urological markers.

PEI- or membrane-coated ELISA detects protein off-target binding faster and with better correlation to in vivo clearance and half-life.

Human anti-FGF2 antibodies block FGF2 signaling to curb melanoma cell proliferation and migration in resistant cancer treatment.

Using silkworms to host implanted medical device materials enables lower-cost, lower-ethics-burden in vivo biofilm evaluation with simpler testing.

Saxiphilin protein analogs enable precise saxitoxin detection in samples while avoiding the complexity of conventional toxin testing systems.

Using soluble RANKL as a binding mediator, this ADA assay improves specificity and reduces false signals in therapeutic antibody testing.

A RuO2 electrode with a molecularly imprinted polymer layer enables direct, selective detection of electrochemically inactive analytes without external redox solutions.

A phosphorylcholine copolymer suppresses heterophile and rheumatoid factor interference while preserving immunoassay sensitivity.

A ligandable tag and labeling enzyme enable in-cell proximity labeling to capture protein-small molecule binding partners at network scale.

An RuO2 electrode coated with a molecularly imprinted polymer detects inactive analytes like BDNF without external redox solutions.

Cancer-targeting ITGA3 antibodies improve ADC delivery by binding and internalizing into tumor cells while reducing normal-cell toxicity.

Targeting the conserved HA stem region yields monoclonal antibodies that broaden influenza A protection and support vaccine antigen quantification.

PEG precipitation and acid dissociation separate drug-ADA complexes, enabling accurate antibody detection even at high drug levels.

Immune marker and cytokine profiling by flow cytometry enables faster, accurate infection diagnosis from small blood samples in remote settings.

Plant- and diatom-derived recombinant antibodies improve immunoassay purity, consistency, and pathogen-free antigen verification.

ATPS phase separation and magnetic concentration isolate tagged viral particles, improving low-load fluorescence detection and reducing false negatives.

Clone-paired human antibodies target diverse henipavirus glycoprotein sites to improve HeV and NiV detection and neutralization.

Air-segmented sample injection in an SPR flow cell avoids buffer washout, preserves sequential analyte interactions, and improves weak binding detection.

A hydrophobic well and supported substrate keep saliva in contact for fast Raman-based virus detection without PCR complexity.

pH-responsive anti-EpCAM antibodies bind more strongly in acidic tumor microenvironments while limiting normal tissue affinity and side effects.

By combining target recycling amplification with PRAM, this assay detects proteins at attomolar to femtomolar levels without complex washing.

Negative-pressure demineralization and alkali treatment extract collagen from teeth and bone while HPLC tracks PYD and pentosidine for quality assessment.

Using recombinant gC as both coating and conjugate, this ELISA cuts false positives in milk-based BoHV-1 antibody testing.

MR-proADM cut-off values enable earlier risk stratification of sepsis, organ failure, and rhabdomyolysis in polytrauma patients.

Novel CD37-binding immunoconjugates use non-cleavable cytotoxic payload delivery to boost apoptosis, CDC, and ADCC while avoiding radio-toxicity.

Targeted CDR sequence changes improve anti-PD1 antibody affinity and specificity while reducing cross-reactivity with related proteins.

Capture zones remove FSH or P3G-linked conjugates before hCG detection, improving pregnancy test specificity in peri- and post-menopausal samples.

Optical resonance sensing enables stable CD44 biomarker detection in blood-mimicking flow while avoiding electrical interference.

Defined anti-ICOS antibody CDRs enable direct IHC detection of ICOS expression, avoiding more complex T-cell activation mechanisms in cancer diagnosis.

Fully human anti-AXL antibodies replace murine sequences to avoid HAMA reactions, extend half-life, and improve cancer targeting.

Optimized anti-AXL CDR sequences improve target specificity and signal-to-noise for detection, diagnosis, and treatment of AXL-related diseases.

Cytokine induction and receptor binding assays improve detection of meteorin-β activity and receptor-expressing cells for research and therapy.

Targets TREM2-positive suppressive myeloid cells for ADCC, ADCP, or CDC depletion to restore antitumor immune responses.

Indirect cytokine readouts and receptor-binding assays make meteorin-β activity and receptor expression measurable for research and therapy.

Sequential platelet removal and CD3+ T cell depletion enrich NK cell compositions while lowering GVHD risk in allogeneic therapy.

Measuring GDF15 propeptide with specific antibodies improves early cancer detection accuracy while reducing false positives across multiple cancers.

Combining a fluorine-containing surfactant with collagen peptide or milk protein suppresses endocrine protein adsorption and stabilizes quantification.

Targeted CDR and framework re-humanization lowers hydrophobicity and improves solubility, conjugation yield, stability, and ADC activity.

Transgenic mice generate fully human AXL antibodies that reduce HAMA immune rejection and extend circulating half-life in cancer use.

Specific Trx1-binding monoclonal antibodies improve breast cancer diagnosis by raising sensitivity and specificity in biological sample detection.

Virus binding adds mass to a resonator surface, shifting frequency for rapid, low-complexity detection without PCR lab equipment.

Specific Trx1 epitope targeting improves antibody affinity, enabling more sensitive and specific breast cancer detection without added diagnostic complexity.